tradingkey.logo

Mangoceuticals Inc

MGRX
0.713USD
-0.597-45.57%
Close 12/19, 16:00ETQuotes delayed by 15 min
9.90MMarket Cap
0.01P/E TTM

Mangoceuticals Inc

0.713
-0.597-45.57%

More Details of Mangoceuticals Inc Company

Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.

Mangoceuticals Inc Info

Ticker SymbolMGRX
Company nameMangoceuticals Inc
IPO dateMar 21, 2023
CEOCohen (Jacob D)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 21
Address15110 Dallas Pkwy, Suite 600
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75248
Phone18336264679
Websitehttps://www.mangorx.com/
Ticker SymbolMGRX
IPO dateMar 21, 2023
CEOCohen (Jacob D)

Company Executives of Mangoceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Kenny Myers
Dr. Kenny Myers
Independent Non-Executive Director
Independent Non-Executive Director
136.67K
+272.72%
Mr. Eugene M. Johnston
Mr. Eugene M. Johnston
Chief Financial Officer
Chief Financial Officer
128.33K
-7.23%
Mr. Alex P. Hamilton
Mr. Alex P. Hamilton
Independent Non-Executive Director
Independent Non-Executive Director
1.67K
-98.68%
Mr. Jacob D. Cohen
Mr. Jacob D. Cohen
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lorraine Dalessio, Esq.
Ms. Lorraine Dalessio, Esq.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kenny Myers
Dr. Kenny Myers
Independent Non-Executive Director
Independent Non-Executive Director
136.67K
+272.72%
Mr. Eugene M. Johnston
Mr. Eugene M. Johnston
Chief Financial Officer
Chief Financial Officer
128.33K
-7.23%
Mr. Alex P. Hamilton
Mr. Alex P. Hamilton
Independent Non-Executive Director
Independent Non-Executive Director
1.67K
-98.68%
Mr. Jacob D. Cohen
Mr. Jacob D. Cohen
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lorraine Dalessio, Esq.
Ms. Lorraine Dalessio, Esq.
Independent Non-Executive Director
Independent Non-Executive Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cohen (Jacob D.)
8.48%
Navy Wharf, Ltd.
6.50%
Propre Energie Inc
4.22%
Greenfield Investments Ltd
3.35%
The Vanguard Group, Inc.
1.25%
Other
76.20%
Shareholders
Shareholders
Proportion
Cohen (Jacob D.)
8.48%
Navy Wharf, Ltd.
6.50%
Propre Energie Inc
4.22%
Greenfield Investments Ltd
3.35%
The Vanguard Group, Inc.
1.25%
Other
76.20%
Shareholder Types
Shareholders
Proportion
Corporation
15.57%
Individual Investor
12.74%
Investment Advisor
1.71%
Investment Advisor/Hedge Fund
0.77%
Venture Capital
0.20%
Other
69.00%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
27
301.64K
2.21%
-28.95K
2025Q2
38
3.44M
29.63%
+1.40M
2025Q1
35
1.92M
37.79%
+1.11M
2024Q4
34
1.29M
45.58%
-18.06K
2024Q3
32
811.21K
40.72%
-490.52K
2024Q2
27
759.36K
45.89%
-544.02K
2024Q1
26
674.02K
59.33%
-527.17K
2023Q4
22
660.62K
58.15%
-532.64K
2023Q3
19
652.27K
63.81%
+112.43K
2023Q2
12
649.40K
63.58%
+115.75K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Cohen (Jacob D.)
1.30M
12.39%
+500.00K
+62.11%
Jul 21, 2025
Navy Wharf, Ltd.
1.00M
9.49%
+1.00M
--
May 27, 2025
Propre Energie Inc
650.00K
6.17%
--
--
May 27, 2025
Greenfield Investments Ltd
515.00K
4.89%
--
--
May 27, 2025
The Vanguard Group, Inc.
182.61K
1.73%
+182.61K
--
Jun 30, 2025
Myers (Kenny)
136.67K
1.3%
+100.00K
+272.72%
Sep 09, 2025
D'Alessio (Lorraine Pamela)
136.67K
1.3%
+100.00K
+272.72%
Sep 09, 2025
Johnston (Eugene M)
138.33K
1.31%
+100.00K
+260.87%
Sep 09, 2025
Geode Capital Management, L.L.C.
26.50K
0.25%
+6.93K
+35.40%
Jun 30, 2025
Isaac (Antonios)
60.00K
0.57%
--
--
May 27, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1
Date
Type
Ratio
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1
Oct 11, 2024
Merger
15→1

FAQs

Who are the top five shareholders of Mangoceuticals Inc?

The top five shareholders of Mangoceuticals Inc are:
Cohen (Jacob D.) holds 1.30M shares, accounting for 12.39% of the total shares.
Navy Wharf, Ltd. holds 1.00M shares, accounting for 9.49% of the total shares.
Propre Energie Inc holds 650.00K shares, accounting for 6.17% of the total shares.
Greenfield Investments Ltd holds 515.00K shares, accounting for 4.89% of the total shares.
The Vanguard Group, Inc. holds 182.61K shares, accounting for 1.73% of the total shares.

What are the top three shareholder types of Mangoceuticals Inc?

The top three shareholder types of Mangoceuticals Inc are:
Cohen (Jacob D.)
Navy Wharf, Ltd.
Propre Energie Inc

How many institutions hold shares of Mangoceuticals Inc (MGRX)?

As of 2025Q3, 27 institutions hold shares of Mangoceuticals Inc, with a combined market value of approximately 301.64K, accounting for 2.21% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -27.42%.

What is the biggest source of revenue for Mangoceuticals Inc?

In --, the -- business generated the highest revenue for Mangoceuticals Inc, amounting to -- and accounting for --% of total revenue.
KeyAI